Maven Securities’s PDS Biotechnology PDSB Stock Holding History

Maven Securities’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-161,305	Closed	-$1.89M	–	1226
2021 Q2	$1.89M	Buy	+161,305	New	+$1.26M	0.08%	250

Other funds holding PDSB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Maven Securities's PDSB Position: Q3 2021 in Review

Maven Securities sold out of PDS Biotechnology (PDSB) in Q3 2021, closing a stake of 161,305 shares — an estimated $1.89M sold.

Maven Securities first reported a position in PDSB in Q2 2021 and held it in 1 quarter. The position peaked at $1.89M in Q2 2021. 59 funds tracked by Wall St. Rank hold PDSB as of Q3 2021.

Maven Securities reported no remaining PDS Biotechnology position as of Q3 2021 after selling out during the quarter.
Maven Securities sold 161,305 PDS Biotechnology shares in Q3 2021, an estimated $1.89M.
Maven Securities first reported a position in PDS Biotechnology in Q2 2021 and held it in 1 quarter.
Maven Securities's PDS Biotechnology position peaked at $1.89M in Q2 2021.
59 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.